Daiichi Sankyo | AstraZeneca

HER2 Knowledge Check+

Identification of HER2 IHC 0+ (with Faint/Incomplete Membrane Staining)

About This Initiative

This educational web-based resource is designed to support pathologists in accurately interpreting low levels of HER2 expression in metastatic breast cancer (mBC) cases using HER2 immunohistochemistry (IHC) staining, with a focus on identifying HER2 IHC 0+ (with faint/incomplete membrane staining).

How It Works

  • Review HER2 IHC staining criteria reference
  • Review and score 5 HER2 IHC staining cases (tap to magnify)
  • Up to 2 attempts per case
  • Digital Pathology Reviews

Medical Disclaimer

For U.S. health care professionals only. This educational resource is intended to support HER2 IHC evaluation and is not a substitute for independent professional judgment, applicable clinical guidelines, or institutional procedures. Final HER2 interpretation, classification, and reporting remain the responsibility of the reviewing pathologist.

©2026 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved. PP-US-8201a-2914-1 10/26 Intended for US HCPs only.

Powered byCognizant&PathPresenter Logo

v0.6.2